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Introduction
Steven-Johnson Syndrome (SJS) is a rapidly progressive mucocutaneous reaction charecterised by immune mediated cell death with extensive epidermal necrosis resulting in severe morbidity and mortality secondary to drugs, infection, Graft versus host reaction [1] . usually presents as a non-specifi c febrile illness with malaise, headache, and rhinorrhea with polymorphic lesions on the skin and mucus membrane.
The incidence has been estimated to be around 1-9/1,000,000 persons per year with a mortality rate upto 5%.Many drugs have been identifi ed as the etiological agents such as sulfonamide derivatives, anticonvulsants such as phenytoin, carbamazepine, Non-steroidal anti-infl ammatory drugs and oxide inhibitors such as allopurinol [2, 3] .
Infections have also been recognized to have a role in occurrence of Steven Johnson Syndrome. [4] .
The exact pathophysiology involved is yet to be elucidated.
It is thought to be a autocrine or paracrine interaction between
Fas and Fas Ligand (FasL) produced by keratinocytes and peripheral mononuclear cells (Soluble type of FasL) resulting in apoptosis of keratinocytes and paucity of T Cell infi ltrates [5, 6] . And in an drug induced SJS the possible mechanism is the expression of specifi c MHC alleles by the keratinocytes on direct contact with granzyme and perforis relased by Drugspecifi c CD8+ cytotoxic T-cells.
Steven-Johnson Syndrome commonly involves the oral mucosa and conjunctiva. Various studies have shown involvement of the conjunctiva in about 49%-81% [7] . And the treatment aims at restoration of the anatomical and physiological properties of the ocular surface [8] .
The present case series is aimed at describing the various ocular manifestation of Steven Johnson Syndrome in different age groups, caused by different agents of variable severity requiring different principles of management. 
Case history

Conclusion
The defi nitive management of Steven Johnson Syndrome remains to be established. The Role of supportive care and identifi cation, with-drawl and reporting of these potential offending drugs is underscored; these are the measures that provide the most proven benefi t. There is no active therapeutic regimen with unequivocal benefi t for treatment of this condition.
It is important for establishment of a defi nitive treatment protocol and an active awareness among clinician's for a safe practice.
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Discussion
The exact aetiopathogenesis of Steven Johnson Syndrome is not known. The role of drugs as an etiological agent is important. The common causative agent have been reported to be drugs belonging to class of long acting sulfonamides and chloroquine [9, 10] . And the understanding of ocular adnexal involvement has been limited so far.
In the acute phase they present with bilateral membranous conjunctivitis and in late stages with alteration ocular surface morphology such as symblepharon, entropion, conjunctival infl ammation, corneal neovascularization with severe xerosis [11, 12] .
The major aim of early intervention is to prevent further complication and in late phases of Steven Johnson Syndrome is reconstruction of ocular surface to correct the chronic infl ammation [8] . The management of late sequelae remains a challenge because of the irreversible alteration in the ocular surface.
Various surgical approaches have been tried and among these, mucus membrane graft is the simplest [13] and the best option when a healthy conjunctival tissue is not available.
Amniotic membrane grafting can also be considered for grafting due to its immense role in maintaining the physiology [14] .
